CA CAPR Capricor Therapeutics Inc Loading... : Bullish and Bearish Analyst Opinions

Shkreli dismisses CAPR as a fraudulent retail name in a reply, but the statement is an opinion without a forward-looking trade call.

Capricor Therapeutics fell 10% after an FDA AdCom was scheduled for July 29, with analysts trimming targets and quant indicators rating it a hold, creating near-term uncertainty ahead of the August 22 PDUFA.

Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A timing framework shows this is the window where acquirers with pre-committed capital execute; sector M&A wave across radiopharmaceuticals, MASH, IBD, and obesity validates the pattern is active.

The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.

The author predicts that Capr will eventually face negative consequences, implying a bearish outlook on the stock's future performance.

Shorting the stock based on the speaker's conviction that the company's clinical data is fraudulent, implying the asset's value is based on false information.

The head of the FDA's division of vaccines and gene therapies set to leave the agency next month... to the expectation maybe a better and some more supportive landscape from the FDA for these kinds of companies. Regulatory bottlenecks are the primary headwind for clinical-stage biotechs. A change in FDA leadership that brings a more lenient or supportive stance will accelerate trial approvals and shorten the timeline to commercialization for biological and gene therapies. LONG. Anticipated deregulation acts as a sector-wide tailwind, disproportionately benefiting small-cap clinical-stage biotechs that rely on smooth FDA pathways. Clinical trials could still fail on efficacy or safety grounds regardless of who is leading the FDA division.

1. THE FACT: The speaker analyzes $CAPR's data, stating "1.2 point improvement on 42 point scale is a 3% improvement vs. placebo -- that can't be stat sig." 2. THE BRIDGE: A 3% improvement is generally considered clinically insignificant, and the speaker's assertion that it "can't be stat sig" (statistically significant) implies the trial results are not robust enough to support efficacy claims. This directly undermines the company's prospects. 3. THE VERDICT: Short CAPR as the reported 3% improvement over placebo is likely not statistically significant, suggesting the drug's efficacy is minimal or non-existent.

1. THE FACT: The speaker states, "i think CAPR failed. it doesn't say prespecified primary endpoint. they're taking the primary endpoint SCALE and doing post-hoc analyses on it!" 2. THE BRIDGE: This reinforces the previous concerns about data manipulation. If the company failed its pre-specified endpoint and is now performing post-hoc analyses on a different measure, it strongly suggests an attempt to salvage negative trial results, which is a bearish signal for the stock. 3. THE VERDICT: Short CAPR as the speaker believes the company's trial failed its pre-specified primary endpoint and is engaging in post-hoc analyses, indicating potential data manipulation and poor trial outcomes.

1. THE FACT: The speaker observes that $CAPR "changed the pre-defined primary endpoint from mean change to % slowing" and states "linda really wants to visit the bureau of prisons." 2. THE BRIDGE: Changing a pre-defined primary endpoint post-hoc is a significant red flag in clinical trials, often done to make unfavorable results appear better. The "bureau of prisons" comment reinforces the severity of this perceived manipulation. 3. THE VERDICT: Short CAPR as the company appears to have changed its primary endpoint, suggesting potential data manipulation and increasing regulatory risk.

1. THE FACT: The speaker directly warns @linda_marban (associated with $CAPR) against lying or spinning data, stating it's "not worth it" and will lead to "law enforcement consequences." 2. THE BRIDGE: This strong warning suggests the speaker has reason to believe CAPR or its representatives might be misrepresenting data, which could lead to regulatory issues or a loss of investor confidence. 3. THE VERDICT: Short CAPR due to the speaker's explicit warning about potential data misrepresentation, which could lead to legal issues or a loss of investor trust.